Treatment options for lysosomal storage disorders: developing insights

Bibliography

• De Duve C, Pressman BC, Gianetto R, Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem J 1955;60(4):604-17
   PubMed Web of Science ®Google Scholar
• Saftig P, Klumperman J. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat Rev Mol Cell Biol 2009;10(9):623-35
   PubMed Web of Science ®Google Scholar
• Eskelinen EL, Tanaka Y, Saftig P. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol 2003;13(3):137-45
   PubMed Web of Science ®Google Scholar
• Luzio JP, Pryor PR, Bright NA. Lysosomes: fusion and function. Nat Rev Mol Cell Biol 2007;8(8):622-32
   PubMed Web of Science ®Google Scholar
• Reczek D, Schwake M, Schroder J, LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 2007;131(4):770-83
   PubMed Web of Science ®Google Scholar
• O'Brien JS, Kishimoto Y. Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J 1991;5(3):301-8
   PubMedGoogle Scholar
• Braulke T, Bonifacino JS. Sorting of lysosomal proteins. Biochim Biophys Acta 2009;Apr1793(4):605-14
   PubMed Web of Science ®Google Scholar
• Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic & molecular bases of inherited disease. 8th edition. McGraw-Hill; New York: 2001
   Google Scholar
• Ruivo R, Anne C, Sagne C, Molecular and cellular basis of lysosomal transmembrane protein dysfunction. Biochim Biophys Acta 2009;1793(4):636-49
   PubMedGoogle Scholar
• Nishino I, Fu J, Tanji K, Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000;406(6798):906-10
   PubMed Web of Science ®Google Scholar
• Blanz J, Groth J, Zachos C, Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand beta-glucocerebrosidase. Hum Mol Genet 2010;19(4):563-72
   PubMedGoogle Scholar
• Velayati A, DePaolo J, Gupta N, A mutation in SCARB2 is a modifier in Gaucher disease. Hum Mutat 2011;32(11):1232-8
   PubMedGoogle Scholar
• Dierks T, Schlotawa L, Frese MA, Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease - Lysosomal storage disorders caused by defects of non-lysosomal proteins. Biochim Biophys Acta 2009;1793(4):710-25
   PubMedGoogle Scholar
• Meikle PJ, Hopwood JJ, Clague AE, Prevalence of lysosomal storage disorders. JAMA 1999;281(3):249-54
   PubMed Web of Science ®Google Scholar
• Poorthuis BJ, Wevers RA, Kleijer WJ, The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105(1-2):151-6
   PubMed Web of Science ®Google Scholar
• Futerman AH, van Meer G. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 2004;5(7):554-65
   PubMed Web of Science ®Google Scholar
• Ballabio A, Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta 2009;1793(4):684-96
   PubMed Web of Science ®Google Scholar
• Castaneda JA, Lim MJ, Cooper JD, Immune system irregularities in lysosomal storage disorders. Acta Neuropathol 2008;115(2):159-74
   PubMed Web of Science ®Google Scholar
• Conzelmann E, Sandhoff K. Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev Neurosci 1984;6(1):58-71
   Google Scholar
• Gieselmann V. What can cell biology tell us about heterogeneity in lysosomal storage diseases? Acta Paediatr Suppl 2005;94(447):80-6; discussion 79
   PubMedGoogle Scholar
• Hers HG. alpha-Glucosidase deficiency in generalized glycogen storage disease (Pompe's disease). Biochem J 1963;1963(86):11-16
   Google Scholar
• De Duve C. From cytases to lysosomes. Fed Proc 1964;23:1045-9
   PubMedGoogle Scholar
• Baudhuin P, Hers HG, Loeb H. An electron microscopic and biochemical study of type II glycogenosis. Lab Invest 1964;13:1139-52
   PubMedGoogle Scholar
• Hug G, Schubert WK. Lysosomes in type II glycogenosis. Changes during administration of extract from Aspergillus niger. J Cell Biol 1967;35:C1-6
   PubMed Web of Science ®Google Scholar
• Tager JM, Hooghwinkel GJM, Daems WT. Enzyme therapy in lysosomal storage disorders. North Holland Publishing Co; Amsterdam: 1974
   Google Scholar
• Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol 1974;41:99-128
   PubMedGoogle Scholar
• Kaplan A, Fischer D, Achord D, Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts. J Clin Invest 2000;74(5):2026-30
   Google Scholar
• Kornfeld S. Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. 1992;61:307-30
   Google Scholar
• Stahl PD, Rodman JS, Miller MJ, Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. Proc Natl Acad Sci USA 1978;75(3):1399-403
   PubMed Web of Science ®Google Scholar
• Furbish FS, Steer CJ, Barranger JA, The uptake of native and desialylated glucocerebrosidase by rat hepatocytes and Kupffer cells. Biochem Biophys Res Commun 1978;81(3):1047-53
   PubMedGoogle Scholar
• Barton NW, Brady RO, Dambrosia JM, Replacement therapy for inherited enzyme deficiency -macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324(21):1464-70
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Barton NW, Pastores G, Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122(1):33-9
   PubMed Web of Science ®Google Scholar
• Morris JL. Velaglucerase alfa for the management of type 1 Gaucher disease. Clin Ther 2012;34(2):259-71
   PubMed Web of Science ®Google Scholar
• Zimran A, Brill-Almon E, Chertkoff R, Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011;118(22):5767-73
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Kopp JB, Austin HA, Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285(21):2743-9
   PubMed Web of Science ®Google Scholar
• Eng CM, Guffon N, Wilcox WR, Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry's disease. N Engl J Med 2001;345(1):9-16
   PubMed Web of Science ®Google Scholar
• Van den Hout H, Reuser AJJ, Vulto AG, Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356(9227):397-8
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Corzo D, Nicolino M, Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68(2):99-109
   PubMed Web of Science ®Google Scholar
• Van der Ploeg AT, Clemens PR, Corzo D, A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010;362(15):1397-406
   Google Scholar
• Wraith JE, Clarke LA, Beck M, Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004;144(5):581-8
   PubMed Web of Science ®Google Scholar
• Muenzer J, Wraith JE, Beck M, A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8(8):465-73
   PubMed Web of Science ®Google Scholar
• Harmatz P, Giugliani R, Schwartz I, Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006;148(4):533-9
   PubMed Web of Science ®Google Scholar
• Clinical trial registry and results database. Available from: http://www.clinicaltrials.gov/ [Last accessed 13 July 2012]
   Google Scholar
• Mistry PK, Wraight EP, Cox TM. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet 1996;348(9041):1555-9
   PubMedGoogle Scholar
• Oussoren E, Brands MMMG, Ruijter GJG, Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options. Biochim Biophys Acta 2011;1812(11):1542-56
   PubMed Web of Science ®Google Scholar
• Brands MMMG, Frohn-Mulder IM, Hagemans MLC, Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI. J Inherit Metab Dis 2012; Epub ahead of print
   PubMedGoogle Scholar
• Ioannou YA, Zeidner KM, Gordon RE, Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 2001;68(1):14-25
   PubMed Web of Science ®Google Scholar
• Bijvoet AG, Van Hirtum H, Kroos MA, Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet 1999;8(12):2145-53
   PubMed Web of Science ®Google Scholar
• Brooks DA. Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol Genet Metab 1999;68(2):268-75
   PubMed Web of Science ®Google Scholar
• Lacana E, Yao LP, Pariser AR, The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease. Am J Med Genet C Semin Med Genet 2012;10:1-10
   Google Scholar
• Fukuda T, Ahearn M, Roberts A, Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol Ther 2006;14(6):831-9
   PubMed Web of Science ®Google Scholar
• Zhu Y, Jiang JL, Gumlaw NK, Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther 2009;17(6):954-63
   PubMed Web of Science ®Google Scholar
• Peng J, Cahayag R, Fox M, Glycogen clearance by BMN 701 and alglucosidase alfa in a mouse model of Pompe disease. Am Soc Human Genetics [Abstract session, 2011]. Available from: http://www.ichg2011.org/cgi-bin/showdetail.pl?absno=21532
   Google Scholar
• Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol 2012;503:269-92
   PubMed Web of Science ®Google Scholar
• Lu JZ, Boado RJ, Hui EKW, Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. Biotechnol Bioeng 2011;108(8):1954-64
   PubMedGoogle Scholar
• Koeberl DD, Li S, Dai J, beta2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Mol Genet Metab 2012;105(2):221-7
   PubMedGoogle Scholar
• Hemsley KM, Hopwood JJ. Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases. Int J Clin Pharmacol Ther 2009;47(Suppl 1):S118-23
   PubMed Web of Science ®Google Scholar
• Munoz-Rojas MV, Vieira T, Costa R, Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet Part A 2008;146A(19):2538-44
   PubMed Web of Science ®Google Scholar
• Beutler E. Lysosomal storage diseases: natural history and ethical and economic aspects. Mol Genet Metab 2006;88(3):208-15
   PubMedGoogle Scholar
• Hobbs JR, Hugh-Jones K, Barrett AJ, Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 1981;2(8249):709-12
   PubMed Web of Science ®Google Scholar
• Krivit W. Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer seminars in immunopathology. Semin Immunopathol 2004;26(1-2):119-32
   PubMed Web of Science ®Google Scholar
• Boelens JJ, Prasad VK, Tolar J, Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr Clin North Am 2010;57(1):123-45
   PubMed Web of Science ®Google Scholar
• Kennedy DW, Abkowitz JL. Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood 1997;90(3):986-93
   PubMed Web of Science ®Google Scholar
• Odorfer KI, Egerbacher M, Unger NJ, Hematopoietic bone marrow cells participate in endothelial, but not epithelial or mesenchymal cell renewal in adult rats. J Cell Mol Med 2011;15(10):2232-44
   PubMedGoogle Scholar
• Aldenhoven M, Boelens JJ, de Koning TJ. The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant 2008;14(5):485-98
   PubMedGoogle Scholar
• Escolar ML, Poe MD, Provenzale JM, Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005;352(20):2069-81
   PubMed Web of Science ®Google Scholar
• Duffner PK, Caggana M, Orsini JJ, Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol 2009;40(4):245-52; 253–5
   PubMed Web of Science ®Google Scholar
• Duffner PK, Caviness VS, Erbe RW, The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York. Genet Med 2009;11(6):450-4
   PubMedGoogle Scholar
• Kogler G, Sensken S, Airey JA, A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004;200(2):123-35
   PubMed Web of Science ®Google Scholar
• Boelens JJ, Wynn RF, O'Meara A, Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 2007;40(3):225-33
   PubMed Web of Science ®Google Scholar
• Koc ON, Day J, Nieder M, Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002;30(4):215-22
   PubMed Web of Science ®Google Scholar
• Shihabuddin LS, Cheng SH. Neural stem cell transplantation as a therapeutic approach for treating lysosomal storage diseases. Neurotherapeutics 2011;8(4):659-67
   PubMed Web of Science ®Google Scholar
• Tolar J, Grewal SS, Bjoraker KJ, Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant 2008;41(6):531-5
   PubMed Web of Science ®Google Scholar
• Priller J, Flugel A, Wehner T, Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat Med 2001;7(12):1356-61
   PubMedGoogle Scholar
• Sands MS, Davidson BL. Gene therapy for lysosomal storage diseases. Mol Ther 2006;13(5):839-49
   PubMed Web of Science ®Google Scholar
• Haskins M. Gene therapy for lysosomal storage diseases (LSDs) in large animal models. ILAR J 2009;50(2):112-21
   PubMed Web of Science ®Google Scholar
• Ioannou YA, Enriquez A, Benjamin C. Gene therapy for lysosomal storage disorders. Expert Opin Biol Ther 2003;3(5):789-801
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302(5644):415-19
   PubMed Web of Science ®Google Scholar
• Hacein-bey-abina S, Garrigue A, Wang GP, Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118(9):3132-42
   PubMed Web of Science ®Google Scholar
• Cheng SH, Smith AE. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther 2003;10(16):1275-81
   PubMed Web of Science ®Google Scholar
• Tomanin R, Zanetti A, Zaccariotto E, Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of Mendelian diseases. Acta Paediatr 2012;101(7):692-701
   PubMedGoogle Scholar
• Worgall S, Sondhi D, Hackett NR, Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008;19(5):463-74
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Y, Boado RJ, Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. Pharm Res 2008;25(2):400-6
   PubMed Web of Science ®Google Scholar
• Valenzano KJ, Khanna R, Powe AC, Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Assay Drug Dev Technol 2011;9(3):213-35
   PubMed Web of Science ®Google Scholar
• Frustaci A, Chimenti C, Ricci R, Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 2001;345(1):25-32
   PubMed Web of Science ®Google Scholar
• Osher E, Fattal-Valevski A, Sagie L, Pyrimethamine increases beta-hexosaminidase A activity in patients with late onset Tay Sachs. Mol Genet Metab 2011;102(3):356-63
   PubMedGoogle Scholar
• Amicus Therapeutics Clinical Trials. Available from: http://amicustherapeutics.com/clinicaltrials/ [Last accessed 13 July 2012]
   Google Scholar
• Clarke JTR, Mahuran DJ, Sathe S, An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Mol Genet Metab 2011;102(1):6-12
   PubMedGoogle Scholar
• Amicus Therapeutics Clinical Trials. Available from: http://amicustherapeutics.com/clinicaltrials/ [Last accessed 27 February 2009]
   Google Scholar
• Maegawa GHB, Tropak MB, Buttner JD, Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 2009;284(35):23502-16
   PubMed Web of Science ®Google Scholar
• Luan Z, Li L, Higaki K, The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice. Brain Dev 2012; Epub ahead of print
   PubMedGoogle Scholar
• Khanna R, Soska R, Lun Y, The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol Ther 2010;18(1):23-33
   PubMed Web of Science ®Google Scholar
• Khanna R, Benjamin ER, Pellegrino L, The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. FEBS J 2010;277(7):1618-38
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Ichinomiya S, Kurosawa M, Therapeutic chaperone effect of N-octyl 4-epi-beta-valienamine on murine G(M1)-gangliosidosis. Mol Genet Metab 2012;106(1):92-8
   PubMedGoogle Scholar
• Ishii S. Pharmacological chaperone therapy for Fabry disease. Proc Jpn Acad Ser B Phys Biol Sci 2012;88(1):18-30
   PubMedGoogle Scholar
• Flanagan JJ, Rossi B, Tang K, The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mut 2009;30(12):1683-92
   PubMed Web of Science ®Google Scholar
• Sawkar AR, Adamski-Werner SL, Cheng WC, Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol 2005;12(11):1235-44
   PubMedGoogle Scholar
• Iwasaki H, Watanabe H, Iida M, Fibroblast screening for chaperone therapy in beta-galactosidosis. Brain Dev 2006;28(8):482-6
   PubMedGoogle Scholar
• Patnaik S, Zheng W, Choi JH, Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J Med Chem 2012;55(4):1553-8
   PubMedGoogle Scholar
• Marugan JJ, Zheng W, Motabar O, Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one analogues as GAA activators. Eur J Med Chem 2010;45(5):1880-97
   PubMedGoogle Scholar
• Shen JS, Edwards NJ, Hong YB, Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase. Biochem Biophys Res Commun 2008;369(4):1071-5
   PubMedGoogle Scholar
• Porto C, Pisani A, Rosa M, Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease. J Inherit Metab Dis 2012;35(3):513-20
   PubMedGoogle Scholar
• Porto C, Cardone M, Fontana F, The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Mol Ther 2009;17(6):964-71
   PubMed Web of Science ®Google Scholar
• Benjamin ER, Khanna R, Schilling A, Co-administration with the pharmacological chaperone AT1001 increases recombinant human alpha-galactosidase A tissue uptake and improves substrate reduction in Fabry mice. Mol Ther 2012;20(4):717-26
   PubMedGoogle Scholar
• Inokuchi J, Radin NS. Preparation of the active isomer of l-phenyl-2-decanoylamino-3-morpholi no-1-propanol, inhibitor of murine glucocerebroside synthetase. J Lipid Res 1987;28(3):565-71
   PubMedGoogle Scholar
• Cox T, Lachmann R, Hollak C, Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355(9214):1481-5
   PubMed Web of Science ®Google Scholar
• Elstein D, Hollak C, Aerts JM, Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 2004;27(6):757-66
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Fitzgibbon EJ, Harris C, Randomized, controlled trial of miglustat in Gaucher's disease type 3. Ann Neurol 2008;64(5):514-22
   PubMed Web of Science ®Google Scholar
• Tylki-Szymanska A, Groener JEM, Kaminski ML, Gaucher disease due to saposin C deficiency, previously described as non-neuronopathic form-no positive effects after 2-years of miglustat therapy. Mol Genet Metab 2011;104(4):627-30
   PubMedGoogle Scholar
• Patterson MC, Vecchio D, Prady H, Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 2007;6(9):765-72
   PubMed Web of Science ®Google Scholar
• Ribas GS, Pires R, Coelho JC, Oxidative stress in Niemann-Pick type C patients: a protective role of N-butyl-deoxynojirimycin therapy. Int J Dev Neurosci 2012; Epub ahead of print
   PubMedGoogle Scholar
• Reuser AJ, Wisselaar HA. An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus. Eur J Clin Invest 1994(3):19-24
   PubMedGoogle Scholar
• Lukina E, Watman N, Arreguin EA, A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 2010;116(6):893-9
   PubMed Web of Science ®Google Scholar
• Lukina E, Watman N, Arreguin EA, Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 2010;116(20):4095-8
   PubMed Web of Science ®Google Scholar
• Friso A, Tomanin R, Salvalaio M, Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol 2010;159(5):1082-91
   PubMed Web of Science ®Google Scholar
• Malinowska M, Wilkinson FL, Bennett W, Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab 2009;98(3):235-42
   PubMed Web of Science ®Google Scholar
• Malinowska M, Wilkinson FL, Langford-Smith KJ, Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS ONE 2010;5(12):e14192
   PubMed Web of Science ®Google Scholar
• Piotrowska E, Jakobkiewicz-Banecka J, Tylki-Szymanska A, Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients. Curr Ther Res 2008;69(2):166-79
   PubMed Web of Science ®Google Scholar
• de Ruijter J, Valstar MJ, Narajczyk M, Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol 2012;71(1):110-20
   PubMed Web of Science ®Google Scholar
• Cherqui S. Cysteamine therapy: a treatment for cystinosis, not a cure. Kidney Int 2012;81(2):127-9
   PubMed Web of Science ®Google Scholar
• Lu JY, Hofmann SL. Inefficient cleavage of palmitoyl-protein thioesterase (PPT) substrates by aminothiols: implications for treatment of infantile neuronal ceroid lipofuscinosis. J Inherit Metab Dis 2006;29(1):119-26
   PubMedGoogle Scholar
• Brooks DA, Muller VJ, Hopwood JJ. Stop-codon read-through for patients affected by a lysosomal storage disorder. Trends Mol Med 2006;12(8):367-73
   PubMed Web of Science ®Google Scholar
• Sarkar C, Zhang Z, Mukherjee AB. Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients. Mol Genet Metab 2011;104(3):338-45
   PubMed Web of Science ®Google Scholar
• Kerem E, Hirawat S, Armoni S, Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008;372(9640):719-27
   PubMed Web of Science ®Google Scholar
• Parekh-Olmedo H, Kmiec EB. Progress and prospects: targeted gene alteration (TGA). Gene Ther 2007;14(24):1675-80
   PubMedGoogle Scholar
• Diaz-Font A, Cormand B, Chabas A, Unsuccessful chimeraplast strategy for the correction of a mutation causing Gaucher disease. Blood Cells Mol Dis 2003;31(2):183-6
   PubMedGoogle Scholar
• Tsuji D, Akeboshi H, Matsuoka K, Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis. Ann Neurol 2011;69(4):691-701
   PubMed Web of Science ®Google Scholar
• Van den Hout JMP, Kamphoven JHJ, Winkel LP, Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004;113(5):e448-57
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126(4):663-76
   PubMed Web of Science ®Google Scholar
• Meng XL, Shen JS, Kawagoe S, Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders. Proc Natl Acad Sci USA 2010;107(17):7886-91
   PubMed Web of Science ®Google Scholar
• Tolar J, Park IH, Xia L, Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). Blood 2011;117(3):839-47
   PubMedGoogle Scholar
• Nakamura K, Hattori K, Endo F. Newborn screening for lysosomal storage disorders. Am J Med Genet C Semin Med Genet 2011;157(1):63-71
   Google Scholar
• Fletcher JM. Screening for lysosomal storage disorders–a clinical perspective. J Inherit Metab Dis 2006;29(2-3):405-8
   PubMedGoogle Scholar